Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
Blood Cancer Journal|January 24, 2023
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcomeJan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig, et al.
Blood Advances|August 30, 2021
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemiaSebastian Stasik, Jan-Niklas Eckardt, Michael Kramer, et al.
Cancers|April 30, 2021
Loss-of-Function Mutations of <i>BCOR</i> Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid LeukemiaJan-Niklas Eckardt, Sebastian Stasik, Michael Kramer, et al.
Haematologica|April 24, 2024
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimensDavid Baden, Sven Zukunft, Gema Hernandez, et al.
Leukemia|October 13, 2023
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemiaJan-Niklas Eckardt, Sebastian Stasik, Christoph Röllig, et al.
Blood|July 28, 2021
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcomeFranziska Taube, Julia Annabell Georgi, Michael Kramer, et al.
European Journal of Cancer (Oxford, England : 1990)|November 26, 2023
A prospective observational study of real-world treatment and outcome in secondary CNS lymphomaStefan Habringer, Uta M Demel, Anne-Katrin Fietz, et al.
Blood|June 5, 2020
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?Christoph Röllig, Michael Kramer, Christoph Schliemann, et al.
Annals of Hematology|July 8, 2025
VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AMLLydia Kretschmer, Leo Ruhnke, Christoph Schliemann, et al.
Leukemia|February 19, 2021
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trialChristoph Röllig, Hubert Serve, Richard Noppeney, et al.
Pageof 7